
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Innov Card Rhythm Manag</journal-id><journal-id journal-id-type="iso-abbrev">J Innov Card Rhythm Manag</journal-id><journal-id journal-id-type="publisher-id">JICRM</journal-id><journal-title-group><journal-title>The Journal of Innovations in Cardiac Rhythm Management</journal-title></journal-title-group><issn pub-type="ppub">2156-3977</issn><issn pub-type="epub">2156-3993</issn><publisher><publisher-name>MediaSphere Medical</publisher-name><publisher-loc>United States</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32494489</article-id><article-id pub-id-type="pmc">7252876</article-id><article-id pub-id-type="publisher-id">icrm.2018.090406</article-id><article-id pub-id-type="doi">10.19102/icrm.2018.090406</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter from the Editor in Chief</subject></subj-group></article-categories><title-group><article-title>Letter from the Editor in Chief</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mansour</surname><given-names>Moussa</given-names></name><degrees>MD, FHRS, FACC</degrees></contrib></contrib-group><pub-date pub-type="epub"><day>15</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2018</year></pub-date><volume>9</volume><issue>4</issue><fpage>A7</fpage><lpage>A7</lpage><permissions><copyright-statement>Copyright: &#x000a9; 2018 Innovations in Cardiac Rhythm Management</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions></article-meta></front><body><p><graphic xlink:href="icrm-09-0A7-g001.jpg" position="float"/></p><p>Dear Readers,</p><p>In the last several years, atrial fibrillation (AF) has become an epidemic in the United States. It is expected that, by the year 2050, between 12 and 15 million people in the country will have AF.<sup><xref rid="r1" ref-type="bibr">1</xref></sup> This is expected to create a huge clinical and economical burden, mostly because of the stroke risk associated with this arrhythmia. Patients with AF are five times more likely to experience a stroke in comparison with those without. Oral anticoagulation is effective in reducing the rate of stroke secondary to AF. However, despite significant advances in the field of pharmacological therapy, only 40% of patients with AF who are at risk of stroke are taking oral anticoagulation.<sup><xref rid="r2" ref-type="bibr">2</xref></sup></p><p>This issue of <italic>The Journal of Innovation in Cardiac Rhythm Management</italic> contains several articles on stroke prevention in patients with AF. I would like to highlight the article by Chava et al.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> reviewing the most recent advances in the field of left atrial appendage (LAA) closure. The authors describe US Food and Drug Administration-approved and investigational LAA closure devices including catheter-based and surgical technologies. They also summarize the findings of landmark clinical trials such as PROTECT AF<sup><xref rid="r4" ref-type="bibr">4</xref></sup> and PREVAIL.<sup><xref rid="r5" ref-type="bibr">5</xref></sup></p><p>This article is important in that it highlights the significance of the field of LAA closure. Historically, this field has been criticized for a lack of robust data. However, this is rapidly changing. Some of the current trials aim to test the efficacy and safety of new LAA closure tools and technological designs, such as the AMPLATZER&#x02122; Amulet&#x02122; LAA Occluder Trial (Amulet IDE) (NCT02879448); the Coherex WAVECREST I Left Atrial Appendage Occlusion Study (NCT02239887); and the Investigational Device Evaluation of the WATCHMAN FLX&#x02122; LAA Closure Technology (PINNACLE FLX) (NCT02702271) study. Others, such as the Assessment of the WATCHMAN&#x02122; Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) (NCT02928497) study, seek to identify new indications for this therapy. As a result, I believe that the next five years will be very exciting for this field.</p><p>I hope that you enjoy reading this issue of <italic>The Journal of Innovations in Cardiac Rhythm Management</italic> and that you find the content educational.</p><p>Sincerely,</p><p><graphic xlink:href="icrm-09-0A7-g002.jpg" position="float"/></p><p>Moussa Mansour, <sc>MD, FHRS, FACC</sc></p><p>Editor-in-Chief</p><p>The Journal of Innovations in Cardiac Rhythm Management</p><p><email>MMansour@InnovationsInCRM.com</email></p><p>Director, Atrial Fibrillation Program</p><p>Jeremy Ruskin and Dan Starks Endowed Chair in Cardiology</p><p>Massachusetts General Hospital</p><p>Boston, MA 02114</p></body><back><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyasaka</surname><given-names>Y</given-names></name><name><surname>Barnes</surname><given-names>ME</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.</article-title><source>Circulation.</source><year>2006</year><volume>114</volume><issue>2</issue><fpage>119</fpage><lpage>125</lpage><comment><ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.1161/CIRCULATIONAHA.105.595140">[CrossRef]</ext-link><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/16818816">[PubMed]</ext-link></comment><pub-id pub-id-type="pmid">16818816</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzec</surname><given-names>LN</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>ND</given-names></name><etal/></person-group><article-title>Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation.</article-title><source>J Am Coll Cardiol.</source><year>2017</year><volume>69</volume><issue>20</issue><fpage>2475</fpage><lpage>2484</lpage><comment><ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.1016/j.jacc.2017.03.540">[CrossRef]</ext-link><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/28521884">[PubMed]</ext-link></comment><pub-id pub-id-type="pmid">28521884</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chava</surname><given-names>R</given-names></name><name><surname>Turagam</surname><given-names>MK</given-names></name><name><surname>Lakkireddy</surname><given-names>D</given-names></name></person-group><article-title>Left atrial appendage occlusion: what are the options and where is the evidence?</article-title><source>J Innov Cardiac Rhythm Manage.</source><year>2018</year><volume>9</volume><issue>4</issue><fpage>3095</fpage><lpage>3106</lpage><pub-id pub-id-type="doi">10.19102/icrm.2018.090402</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>VY</given-names></name><name><surname>Holmes</surname><given-names>D</given-names></name><name><surname>Doshi</surname><given-names>SK</given-names></name><name><surname>Neuzil</surname><given-names>P</given-names></name><name><surname>Kar</surname><given-names>S</given-names></name></person-group><article-title>Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.</article-title><source>Circulation.</source><year>2011</year><volume>123</volume><issue>4</issue><fpage>417</fpage><lpage>424</lpage><comment><ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.1016/S0140-6736(09)61343-X">[CrossRef]</ext-link><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/19683639">[PubMed]</ext-link></comment><pub-id pub-id-type="pmid">21242484</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>DR</given-names></name><name><surname>Kar</surname><given-names>SK</given-names></name><name><surname>Price</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus longterm warfarin therapy: the PREVAIL trial.</article-title><source>J Am Coll Cardiol.</source><year>2014</year><volume>64</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.04.029</pub-id><pub-id pub-id-type="pmid">24998121</pub-id></element-citation></ref></ref-list></back></article>